None
Quote | Photocure Asa (OTCMKTS:PHCUF)
Last: | $5.95 |
---|---|
Change Percent: | 0.0% |
Open: | $5.95 |
Close: | $5.95 |
High: | $5.95 |
Low: | $5.95 |
Volume: | 100 |
Last Trade Date Time: | 03/06/2024 03:00:00 am |
News | Photocure Asa (OTCMKTS:PHCUF)
The following slide deck was published by Photocure ASA in conjunction with their 2023 Q4 earnings call. For further details see: Photocure ASA 2023 Q4 - Results - Earnings Call Presentation
Photocure ASA press release ( OTC:PHCUF ): Q4 GAAP EPS of -NOK 0.79. Revenue of NOK 104.2M (+10.3% Y/Y). The EBIT was -NOK 23.1 million (-NOK 11.5 million) and the cash balance at the end of the third quarter 2022 was NOK 268.1 million. "We expect to deliver Hex...
Message Board Posts | Photocure Asa (OTCMKTS:PHCUF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Photocure ASA (PHCUF) Headlines Acne Vulgaris Global Clinical Trials Review, H | Stock_Tracker | investorshangout | 03/11/2014 4:05:04 AM |
chartguy89: PHCUF 4.15 Stock Charts $PHCUF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 9:55:19 AM |
chartguy89: PHCUF Stock Charts Last: UNCH Friday, February 28, 2014 at 11:41:02 PM $PHCUF 1 | chartguy89 | investorshangout | 03/01/2014 4:41:13 AM |
News, Short Squeeze, Breakout and More Instantly...
Photocure Asa Company Name:
PHCUF Stock Symbol:
OTCMKTS Market:
Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial PR Newswire OSLO, Norway , Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022 , Asieris Pharmaceuticals, a global biopharmaceutical company specializ...
Photocure ASA: Results for the first quarter of 2022 PR Newswire OSLO, Norway , May 11, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 81.4 million in the first quarter of 2022 (Q1 ...
Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China PR Newswire OSLO, Norway , March 11, 2022 /PRNewswire/ -- Photocure ASA ( PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...